Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 108, Issue 7, Pages 2421-2429Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2019.02.022
Keywords
formulation; immunotherapy; mucosal immunization; oral drug delivery; nanoparticles; protein delivery; vaccine adjuvants
Funding
- European Community [NMP-2011-1.2-2-28076]
- Asociacion de Amigos Universidad de Navarra
Ask authors/readers for more resources
Peanut allergy is one of the most prevalent and severe of food allergies with no available cure. The aim of this work was to evaluate the potential of an oral immunotherapy based on the use of a roasted peanut extract encapsulated in nanoparticles withimmunoadjuvant properties. For this, a polymer conjugate formedby the covalent binding of mannosamine to the copolymer of methyl vinyl ether and maleic anhydride was first synthetized and characterized. Then, the conjugate was used to prepare nanoparticles with an important capability to diffuse through the mucus layer and reach, in a large extent, the intestinal epithelium, including Peyer's patches. Their immunotherapeutic potential was evaluated in a model of presensitized CD1 mice to peanut. After completing therapy, mice underwent an intraperitoneal challenge with peanut extract. Nanoparticle-treatment was associated with both less serious anaphylaxis symptoms and higher survival rates than control, confirming the protective effect of this formulation against the challenge. (c) 2019 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available